Merck Asks FDA to Authorize Promising Covid-19 Pill
The filing comes shortly after data from a late-stage study showed that the antiviral drug, molnupiravir, cut the risk of hospitalization or death by about 50% in high-risk people with mild to moderate Covid-19.
This post was originally published on Market Watch
